Cholangiocarcinomas Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02393248Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Treatment